Ocular Therapeutix’ Axpaxli shows superiority over Eylea, shares sink
欧库拉疗法的Axpaxli优于Eylea，股价下挫

Ocular Therapeutix’ investigational drug could become the preferred therapy for wet age-related macular degeneration after data released Tuesday showed statistical superiority to Regeneron and Bayer’s current bestseller Eylea.
周二公布的数据表明，欧库拉疗法的一款在研药物在疗效上具有统计学优势，相比再生元与拜耳的现有畅销药物Eylea，有望成为湿性年龄相关性黄斑变性（湿性AMD）的优选疗法。